— Alkermes’ Novel Immuno-Oncology Drug Candidate Demonstrated Preferential Expansion and Tumor Infiltration of Select Tumor-Killing Immune Cells in Preclinical Xenograft Model of Metastatic Melanoma —
“These data add to the growing body of evidence supporting the unique
profile of ALKS 4230, a novel immuno-oncology candidate designed to
harness the IL-2 mechanism in a selective way to enhance anti-tumor
activity with the potential for improved safety and tolerability,” said
In the preclinical data presented at
A poster on the preclinical data, titled, “A Novel, Individualized
Xenograft Model of Cancer Immunotherapy and Tumor Growth Inhibition by
ALKS 4230,” will be presented by Dr.
About ALKS 4230
ALKS 4230 is an
engineered fusion protein designed to preferentially bind and signal
through the intermediate affinity interleukin-2 (IL-2) receptor complex,
thereby selectively activating and increasing the number of
immunostimulatory tumor-killing immune cells while avoiding the
expansion of immunosuppressive cells that interfere with anti-tumor
response. The selectivity of ALKS 4230 is designed to leverage the
proven anti-tumor effects while overcoming limitations of existing IL-2
therapy, which activates both immunosuppressive and tumor-killing immune
cells.
About Alkermes
Note Regarding Forward-Looking Statements
Certain
statements set forth in this press release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including, but not limited to,
statements concerning the potential therapeutic value of, and clinical
development plans for, ALKS 4230. You are cautioned that forward-looking
statements are inherently uncertain. Although the company believes that
such statements are based on reasonable assumptions within the bounds of
its knowledge of its business and operations, the forward-looking
statements are neither promises nor guarantees and are subject to a
variety of risks and uncertainties, many of which are beyond the
company’s control, which could cause actual results to differ materially
from those expressed or implied in the forward-looking statements. These
risks and uncertainties include, among others, whether preclinical
results for ALKS 4230 will be predictive of future clinical study
results; whether ALKS 4230 could be shown to be unsafe or ineffective;
whether future clinical trials for ALKS 4230 will be initiated or
completed on time or at all; changes in the cost, scope and duration of
ALKS 4230 clinical trials; and those risks and uncertainties described
under the heading “Risk Factors” in the company’s Annual Report on Form
10-K for the year ended
View source version on businesswire.com: http://www.businesswire.com/news/home/20171108005153/en/
Source:
Alkermes
For Investors:
Eva
Stroynowski, +1 781-609-6823
or
Sandy Coombs, +1 781-609-6377
or
For
Media:
Jennifer Snyder, +1 781-609-6166